The Rainwater Charitable Foundation is a brand dedicated to accelerating the development of new treatments for Alzheimer's disease, frontotemporal dementias, and other neurodegenerative diseases involving the dysfunctional tau protein. With a sense of urgency and a focus on patient well-being, the foundation collaborates with scientists, engages strategic partners, and provides critical resources to understand the underlying causes of these diseases. Since its establishment in 2009, the Rainwater Charitable Foundation has invested over $100 million in the Tau Consortium, resulting in eight treatments entering human trials.

In addition to funding specific projects, the foundation serves as a valuable resource for the academic research field, industry players, funding partners, and policy makers. They host international conferences and have launched a major prize program to foster scientific progress in the field of neurodegenerative diseases. The foundation's goal is to create collaborative networks of scientists working towards better treatments for patients by unraveling the mysteries of tau-related disorders.

By focusing on the tau protein, which is associated with various neurodegenerative diseases, the Rainwater Charitable Foundation aims to bring us closer to effective treatments